Abstract
Background: Cost-effectiveness analyses of preventive screening strategies are paramount for public health to ensure the effective resource use, especially for sexually transmitted infections such as Chlamydia, which lead to significant Quality-Adjusted Life Years (QALY) loss. Summary: This study systematically reviewed EMBASE, PubMed and SCOPUS databases, from inception to October 2022, Chlamydia infection screening strategies' cost-effectiveness studies analyzing Incremental Cost Effectiveness Ratio (ICER) of QALYs versus no screening. Out of 487 studies, six were included, each employing distinct screening approaches, assumptions, and prevalence and incidence rates. The ICERs varied from $2,350/QALY gained with annual screening of women aged 15 to 24 years to €117,529 /QALY gained with women and men screening (age 16-29). Key Messages: The results underscore the impact of the different assumptions on ICERs and highlights the importance of precise epidemiology on Chlamydia infections. Studies characterizing the local population are crucial for accurate cost-effectiveness analysis and public health policy formulation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
